ALBO - Albireo And Odevixibat In Orphan Pediatric Cholestatic Liver Diseases: Making Magnificent Progress
Introduction
Albireo (ALBO) is one or the only publicly-listed biopharma that has an orphan pediatric cholestatic liver diseases clinical program. Albireo through its unique drug pipeline employs a distinct mechanistic approach to dealing with the distressing adverse event of pruritus (i.e. intense itching) associated with rare pediatric cholestatic liver diseases. The lead investigative drug candidate, Odevixibat (formerly A4250), is in mid-late phase clinical trials for orphan pediatric cholestatic liver diseases, Progressive Familial Intrahepatic Cholestasis ((PFIC)), Alagille syndrome, and Biliary Atresia.
Albireo is a small market cap ($389M) commercial-stage biopharma that is still under